Cagrilintide 15mg — Vial Spec, Reconstitution Math & COA

Overview of the 15mg Cagrilintide Vial Specification

A 15mg vial of Cagrilintide contains 15 milligrams of highly purified, lyophilized acylated peptide powder, specifically engineered as a long-acting non-selective amylin and calcitonin receptor agonist for in vitro assays and preclinical animal models. This high-mass unit configuration is typically selected by research institutions conducting large-cohort preclinical trials, automated high-throughput receptor binding screens, or longitudinal metabolic rate investigations where consistent batch uniformity across multiple assay plates is mandatory.

In standardized benchwork, ordering a 15mg high-mass vial minimizes inter-vial variance across extended assay runs. While standard analytical protocols often utilize lower mass increments, higher yield specifications allow core facilities to prepare stock solutions that support multiple assay replicates without re-establishing baseline concentrations. Researchers seeking standard catalog configurations or alternate mass yields can review our primary Cagrilintide catalog entry or explore our complete catalog of all research peptides to align vial selections with specific experiment design requirements.

Please note that PX1 Research supplies peptides exclusively for laboratory research and analytical testing. If a 15mg format is not actively listed in our primary inventory dropdown, custom high-mass fills and bulk lot allocations can be arranged through our institutional account program for verified laboratory partners.

Molecular Identity and Receptor Binding Mechanisms

Cagrilintide is a synthetic lipopeptide derivative modeled after endogenous human amylin (islet amyloid polypeptide, or IAPP). Biochemically, it is engineered via targeted amino acid substitutions and C16 fatty acid acylation at specific lysine residues. This lipophilic modification increases plasma protein binding—specifically albumin association—which dramatically extends its structural integrity and active half-life in preclinical rodent models compared to native amylin.

In cell-free and cell-based signaling assays, Cagrilintide functions as a potent dual agonist at both human amylin receptors (AMYR1, AMYR2, and AMYR3) and the human calcitonin receptor (CTR). Preclinical data indicate that simultaneous activation of CTR and receptor activity-modifying proteins (RAMPs) initiates intracellular cyclic adenosine monophosphate (cAMP) accumulation. Researchers investigating metabolic signaling pathways utilize this peptide to evaluate homeostatic feeding regulation, gastric emptying kinetics, and central energy expenditure mechanisms in controlled laboratory environments.

Volumetric Reconstitution Mathematics for 15mg Lyophilized Mass

Accurate reconstitution of high-mass peptide vials requires strict adherence to volumetric protocols to ensure precise micromolar or millimolar dosing in assay wells. When reconstituting a 15mg lyophilized cake, liquid diluent volume determines the final working concentration per microliter (µL). Laboratory technicians should use sterile Bacteriostatic Water (0.9% benzyl alcohol) for multi-use analytical workflows, or sterile 0.9% Sodium Chloride for sensitive cell culture applications where preservatives may interfere with cellular viability.

The following reconstitution parameters apply to a standard 15mg (15,000 µg) Cagrilintide mass load:

1.0 mL Diluent Addition: Yields a concentration of 15.0 mg/mL (15.0 µg/µL, or 15,000 µg/mL). This high-density stock solution is ideal for compact storage or preparing primary concentration gradients where minimal diluent volume can be added to assay media.

2.0 mL Diluent Addition: Yields a concentration of 7.5 mg/mL (7.5 µg/µL, or 7,500 µg/mL). This intermediate concentration provides an optimal balance between volumetric accuracy during micro-pipetting and stock solution conservation.

3.0 mL Diluent Addition: Yields a concentration of 5.0 mg/mL (5.0 µg/µL, or 5,000 µg/mL). This lower concentration is recommended when working with automated fluid handlers or manual pipettes that require larger volumetric draws to maintain precision within ±1%.

To quickly verify custom dilutions, calculate target concentrations, or adjust for specialized buffer gravities, researchers should utilize the interactive PX1 Research reconstitution calculator prior to solvent introduction.

Aliquot Planning, Diluent Selection, and Handling Protocols

Because reconstituted peptides are subject to hydrolytic degradation and potential peptide aggregation, establishing an aliquot strategy immediately following solvent addition is critical. Repeated freeze-thaw cycles disrupt the secondary structure of acylated peptides, accelerating degradation and leading to inconsistent experimental outcomes. For a 15mg vial, researchers should calculate total assay volume demands and divide reconstituted solutions into single-use polypropylene micro-centrifuge tubes.

When introducing diluent into the vial, direct the stream down the glass interior wall rather than spraying directly onto the lyophilized cake. Allow the cake to dissolve naturally via passive hydration for 5–10 minutes, followed by gentle side-to-side swirling. Never vortex or aggressively shake reconstituted Cagrilintide, as mechanical shear stress can induce protein denaturation, aggregation, or precipitation out of solution.

For prolonged storage of reconstituted aliquots, maintain stock samples at -20°C or -80°C in low-retention micro-tubes to prevent non-specific binding of lipophilic peptides to container walls. Working aliquots held at 2–8°C should be utilized within 14 to 28 days depending on the presence of antimicrobial preservatives such as benzyl alcohol.

Lot-Matched COA Verification: HPLC, Mass Spec, and Endotoxin Standards

Every production lot of Cagrilintide synthesized for PX1 Research undergoes rigorous testing in an ISO 17025 accredited laboratory to verify identity, purity, and safety. Due to the high mass density of 15mg vials, analytical precision is paramount to guarantee that no synthesis byproducts or residual truncated sequences compromise quantitative research.

Analytical documentation provided with each lot includes High-Performance Liquid Chromatography (HPLC) chromatograms confirming a chemical purity profile of ≥99.0%. Mass Spectrometry (MS) electrospray ionization profiles confirm the exact target molecular weight, validating the correct primary amino acid sequence and acylation placement. Furthermore, because bacterial endotoxins can induce non-specific inflammatory signaling in target cell lines or preclinical animal tissue, each lot undergoes Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels strictly below 0.01 EU/mg. Primary investigators can access, download, and review authentic lot-specific documentation directly via our dedicated certificate of analysis portal.

Comparative Analysis: Amylin Agonists vs. Incretin Co-Agonists

In preclinical metabolic research, understanding the distinct signaling profiles of novel compounds compared to established mono- and dual-agonists is essential for experimental design. While traditional incretin mimetics focus primarily on glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide (GIP) pathways, Cagrilintide operates through parallel neuro-endocrine mechanisms involving amylin and calcitonin receptors.

When designing comparative co-administration or head-to-head in vitro trials, researchers frequently evaluate Cagrilintide alongside pure GLP-1 receptor agonists such as semaglutide, dual GLP-1/GIP receptor agonists such as tirzepatide, and tri-agonists like retatrutide. While incretin agonists modulate insulin secretion and peripheral glucose uptake, amylin-calcitonin agonists primarily modulate central satiety signaling, delay gastric emptying in rodent models, and suppress postprandial glucagon secretion. Combining an amylin receptor agonist with an incretin agonist provides a synergistic research paradigm for investigating multi-pathway body weight regulation and metabolic homeostasis.

Selecting Optimal Mass Formats: 15mg vs. Standard 5mg/10mg Vials

Choosing between a 15mg high-mass vial and standard catalog sizes (such as 2mg, 5mg, or 10mg) depends on experimental scale, duration, and storage capabilities. A 15mg vial offers distinct advantages for high-volume research protocols, including reduced overall packaging waste, streamlined storage footprint, and identical batch characteristics across high-density screening plates.

Conversely, if an experimental protocol calls for infrequent dosing in small rodent cohorts, selecting smaller mass units (e.g., 5mg) may be more advantageous. Smaller units reduce the duration a reconstituted solution remains in liquid storage, minimizing potential degradation risks over time. Principle investigators managing large-scale facility contracts or multi-project laboratories can consult our wholesale institutional support team to structure custom fill volumes, batch lock arrangements, or recurring shipment schedules tailored to project timelines.

Storage Parameters and Cold-Chain Supply Integrity

To preserve the bioactivity and structural stability of Cagrilintide 15mg vials, strict environmental temperature controls must be maintained from manufacturing through delivery and laboratory storage. Unreconstituted lyophilized vials should be stored in a dry, dark environment at -20°C for short-to-medium term storage, or at -80°C for long-term archival purposes. Under these conditions, the lyophilized peptide cake remains stable for up to 24 months.

PX1 Research operates state-of-the-art dispatch facilities in California and Arizona, utilizing temperature-monitored, insulated packaging to prevent thermal degradation during transit. All orders placed Monday through Friday before cut-off times are dispatched same-day. Upon receipt at the research facility, vials should be inspected immediately and placed into dedicated cold-storage units prior to reconstitution. Additional technical background on peptide stability kinetics can be found in our scientific research library.